Sleep apnea biotech breathes easy with $62.5M financing ahead of PhIII trials for lead oral drug

Lei Lei Wu

News Reporter

Traditional care for obstructive sleep apnea involves CPAP, a cumbersome countermeasure in which patients have air continuously pushed through a mask they have to wear …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sleep apnea biotech breathes easy with $62.5M financing ahead of PhIII trials for lead oral drug

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sleep ap­nea biotech breathes easy with $62.5M fi­nanc­ing ahead of PhI­II tri­als for lead oral drug

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sleep apnea biotech breathes easy with $62.5M financing ahead of PhIII trials for lead oral drug